Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (I.R.S. Employer Identification No.) PO Box 13628, 68 TW Alexander Drive Research Triangle Park, North Carolina (Address of Principal Executive Offices) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____ to ____ Commission File Numbe ...

Rosty Raykov - Chief Executive Officer and Director Robert Andrade - Chief Financial Officer Adrian Haigh - Chief Operating Officer Good morning, ladies and gentlemen. And welcome to the Fennec Pharmaceuticals' First Quarter 2024 Earnings and Corporate Update Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question-and-answer session and instructions on how to participate will be given at that time. As a reminder, today's conference is being recorded. And ...

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -16.33%. A quarter ago, it was expected that this company would post earnings of $0.02 per share when it actually produced a loss of $0.10, delivering a surprise of -600%. Over the last four quarters, the co ...

~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement with Norgine to Commercialize PEDMARQSI™ in Europe, Australia, and New Zealand ~ ~ Amended PEDMARK Permanent J-code 07901 Became Effective April 1, 2024 ~ ~ Company Has Approximately $51 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RE ...

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May 14, 2024Tim ...

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May 14, 2024Time: ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 20-0442384 (State ...

Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved PEDMARK Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI™ in Europe, Australia and New Zealand for Approximately $43 Million Upfront and Up to Approximately $230 Million in Additional Commercial and Regulatory Milestones, and ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Results Conference Call March 21, 2024 8:30 AM ET Robert Andrade - Chief Financial Officer Rosty Raykov - Chief Executive Officer Adrian Haigh - Chief Operating Officer Operator Company Participants Conference Call Participants Naureen Quibria - Capital One Securities Chase Knickerbocker - Craig-Hallum Dipesh Patel - H.C. Wainwright Good morning, ladies and gentlemen. And welcome to the Fennec Pharmaceuticals' Fourth Quarter and Full Year 2023 Earnings and C ...

Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -600%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.07, delivering a surprise of 36.36%.Over the last four quarters, the company has surpassed ...